SKELID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Skelid, and when can generic versions of Skelid launch?
Skelid is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in SKELID is tiludronate disodium. There is one drug master file entry for this compound. Additional details are available on the tiludronate disodium profile page.
Summary for SKELID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 88 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,264 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | SKELID at DailyMed |
Recent Clinical Trials for SKELID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assistance Publique - Hôpitaux de Paris | Phase 3 |
US Patents and Regulatory Information for SKELID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SKELID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Sanofi Aventis Us | SKELID | tiludronate disodium | TABLET;ORAL | 020707-001 | Mar 7, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SKELID
See the table below for patents covering SKELID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 3374062 | ⤷ Try a Trial | |
| South Africa | 8305578 | ⤷ Try a Trial | |
| Latvia | 5524 | Panemiens metilendifosfonskabes atvasinajumu iegusanai | ⤷ Try a Trial |
| Canada | 1327009 | COMPOSITION PHARMACEUTIQUE POUR ADMINISTRATION PAR VOIE ORALE, A BASE D'UN DERIVE D'ACIDE DIPHOSPHONIQUE (PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, BASED ON A DIPHOSPHONIC ACID DERIVATIVE) | ⤷ Try a Trial |
| Ireland | 831716 | ⤷ Try a Trial | |
| Finland | 832758 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SKELID
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0100718 | SPC/GB96/027 | United Kingdom | ⤷ Try a Trial | |
| 0100718 | 96C0006 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TILUDRONATE DISODIQUE EXPRIME EN ACIDE TILUDRONIQUE; NAT. REGISTRATION NO/DATE: 201 IS 106 F 3 19950907; FIRST REGISTRATION: LI 53014 19950220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
